• The risk of thrombosis among ischemic stroke patients using glucocorticoids is unknown.
Introduction
Stroke is a major cause of disability, and is expected to remain a leading cause of death worldwide in the coming decades [1, 2] . First-time stroke occurs in~600 000 Americans each year [3] , with a 30-day mortality rate of~11% for ischemic stroke [4] .
Glucocorticoids are widely used, despite being potent immunosuppressive agents [5] with an array of side effects [6] , An estimated 3% of all Danes redeem at least one systemic glucocorticoid prescription each year [7] . Among ischemic stroke patients, glucocorticoids may have beneficial effects relating to control of cerebral edema during the course of stroke. Such edema exerts pressure on surrounding structures, causing direct vascular occlusion and vasospasm, with subsequent clinical deterioration or death [8] . Possible negative effects of glucocorticoids could be mediated through adrenal suppression, which compromises the cortisol response to critical illness such as ischemic stroke [6] . Glucocorticoids are known to induce both a procoagulant state and a prothrombotic state, which may promote the formation of venous and arterial thrombi [6] . Also, exogenous glucocorticoid supplements may cause hyperglycemia, insulin resistance, dyslipidemia, and the development of metabolic syndrome, which is a risk factor for both venous and arterial thrombus formation [9] . Finally, the cardiovascular system may be stressed additionally in glucocorticoid users through a mineralocorticoid-like effect, increasing plasma volume and blood pressure, and thereby precipitating arterial thrombotic events [9] .
In previous research, preadmission use of glucocorticoids has been associated with a 1.6-fold increase in 30-day mortality following ischemic stroke [10] . However, the clinical pathways responsible for excess mortality in glucocorticoid users who suffer a stroke are unknown. We therefore examined the impact of preadmission use of glucocorticoids on the risks of recurrent ischemic stroke, hemorrhagic stroke, myocardial infarction and venous thromboembolism following ischemic stroke.
Materials and methods
The data, analytical methods and other study materials will not be made available to other researchers for purposes of reproducing the results or replicating the study. Such disclosure would conflict with the regulations for the use of Danish healthcare data.
Design and setting
We conducted a nationwide population-based cohort study in Denmark from 1 July 2004 to 1 July 2013. During this time period, the total cumulative underlying population at risk was 6 541 791 inhabitants. The study period started 6 months after the initiation of the Danish National Health Service Prescription Database on 1 January 2004, to ensure the availability of at least 6 months of preadmission prescription history for all participants [11] . The Danish healthcare system provides free and unfettered access to general practitioners and hospitals for the entire population, and partly refunds the costs of prescribed medication, including systemic glucocorticoids [11] . In Denmark, care for patients with medical emergencies, including stroke, is provided by public hospitals [12] . We linked medical registries by using the unique 10-digit central personal registry number assigned to each Danish citizen at birth and to residents upon immigration [13] .
Patients with ischemic stroke
We used the Danish National Patient Registry (DNPR) [14] to identify all persons in the Danish population with a first-time inpatient hospitalization for ischemic stroke during the study period. The DNPR contains data on admission and discharge dates and discharge diagnoses from all Danish non-psychiatric hospitals since 1977 and on emergency room and outpatient clinic visits since 1995 [14] . Each hospital discharge or outpatient visit is assigned one primary diagnosis, and up to 19 secondary diagnoses classified according to the International Classification of Diseases, Eighth Revision until the end of 1993 and the International Classification of Diseases, Tenth Revision (ICD-10) thereafter [14] . Both primary and secondary diagnoses were used to identify patients with first-time ischemic stroke. For each specific study outcome (recurrent ischemic stroke, hemorrhagic stroke, myocardial infarction, and venous thromboembolism), we excluded ischemic stroke patients with a previous or concurrent inpatient or outpatient diagnosis of the given outcome to avoid bidirectional associations. As approximately two-thirds of all unspecified strokes (ICD-10 code: I64) are known to be ischemic strokes (ICD-10 code: I63), we classified unspecified strokes (40% of all stroke diagnoses) as ischemic strokes [15] . Codes used in the study are provided in Tables S1 and S2 .
Glucocorticoid use
We used the Danish National Health Service Prescription Database to identify all prescriptions redeemed by study participants for systemic glucocorticoids [11] . On the basis of methods used previously [10] , we defined current users as patients who redeemed their most recent prescription within 90 days before hospital admission for ischemic stroke. Current users were categorized further into new users, who redeemed their first-ever prescription within 90 days before admission, and long-term users, who redeemed their first-ever prescription > 90 days before admission. We defined former users as patients whose last prescription redemption was between 90 and 180 days before admission. Non-users (i.e. individuals who had no prescriptions for any glucocorticoids within 180 days before admission) constituted the reference cohort in all comparisons.
For current users, we computed prednisolone-equivalent cumulative doses as described previously [10] to examine any dose-response effects. Briefly, the prednisolone-equivalent cumulative dose was obtained by multiplying the number of pills/injections 9 dose per pill/injection 9 prednisone conversion factor for each prescription, and then summing across all prescriptions redeemed within 90 days of admission (current use) [10] .
Outcomes
Outcomes were all first-time hospitalizations registered in the DNPR with primary and secondary inpatient diagnoses of myocardial infarction and venous thromboembolism after the index date, defined as the admission date for ischemic stroke. However, we restricted the outcomes of recurrent ischemic stroke and hemorrhagic stroke to primary inpatient diagnoses, to reduce coding errors related to the initial admission and subsequent outpatient follow-up after stroke. We classified outcomes of unspecified strokes as ischemic strokes.
Patient characteristics
We used the complete inpatient and outpatient medical history available in the DNPR [14] to ascertain the presence of potentially confounding comorbidities. The DNPR provided information on known prognostic factors (atrial fibrillation or flutter, intermittent arterial claudication, and diabetes) [16] and on other potential confounders with a prognostic impact on ischemic stroke or an association with glucocorticoid use, including angina pectoris, hypertension, rheumatoid arthritis and related diseases, connective tissue disease, chronic obstructive pulmonary disease, inflammatory bowel disease, obesity, chronic kidney disease, alcoholism-related diseases, and cancer. To increase the sensitivity of diagnoses of hypertension, diabetes, chronic obstructive pulmonary disease, and alcoholism-related diseases, we used both hospital-based diagnoses and any redeemed prescriptions for disease-specific medication based on data from the prescription database [11] .
Comedications
We obtained information from the prescription database [11] on concurrent use (i.e. ≤ 90 days before admission) of nitrates (if two or more prescriptions were registered), statins, aspirin, clopidogrel, vitamin K antagonists, selective serotonin reuptake inhibitors, and non-aspirin nonsteroidal anti-inflammatory drugs.
Statistical analysis
We characterized patients with ischemic stroke according to age group (< 60, 60-69, 70-79 and ≥ 80 years), sex, comorbidities, and comedications (Table 1) . For each analysis, we followed ischemic stroke patients from their index date until the occurrence of an outcome, emigration, death, 1 year of follow-up, or 31 November 2013, whichever came first. We restricted follow-up to 1 year to ensure a temporal relationship between glucocorticoid exposure and cardiovascular events. Multiple outcomes for the same patient did not affect study eligibility, but only the first incident event for each outcome of interest was included in the analysis.
Using cumulative incidence functions with death as a competing risk, we illustrated the cumulative risk of the outcomes during follow-up for current users and nonusers. We used Cox proportional-hazards regression to estimate the unadjusted hazard ratio and adjusted hazard ratio (aHR) among current, new, long-term and former users as compared with non-users within 1 year of followup. For all estimates, we computed 95% confidence intervals (CIs).
We performed analyses stratified by ischemic stroke diagnosis type (specified versus unspecified), sex, age group, cardiovascular disease, rheumatoid arthritis and related diseases, connective tissue disease, chronic pulmonary disease, inflammatory bowel disease, study period (2004-2008 and 2009-2013) , and provoked versus unprovoked venous thromboembolism. Provoked venous thromboembolism was defined as a diagnosis of malignancy at any time before the diagnosis of venous thromboembolism, or pregnancy/delivery, fracture/trauma or surgery within 90 days prior to the venous thromboembolism diagnosis. We also compared current use of glucocorticoids directly with former use, to evaluate the extent of confounding by indication.
We performed two sensitivity analyses. First, to increase the positive predictive value of the ischemic stroke diagnosis, we restricted the analyses to patients who had a computed tomography or magnetic resonance imaging scan registered in the DNPR during hospitalization for ischemic stroke. Second, to examine the impact of differences in exposure definitions, we repeated the analysis with substitution of the 90-day exposure window with 60-day and 30-day exposure windows.
All statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA). According to Danish legislation, informed consent and approval from an ethics committee is not required for registry-based studies. The study was approved by the Danish Data Protection Agency (record number: 2011-41-5755).
Results

Patient characteristics
Patient characteristics are shown in Table 1 . We identified 98 487 patients with a first-time ischemic stroke between 2004 and 2013. A total of 4677 patients (4.7%) were current users of glucocorticoids, 1564 (1.6%) were former users, and 92 246 (93.7%) were non-users. Women were overrepresented among current and former glucocorticoid users. All cardiovascular diseases, obesity, diabetes mellitus, chronic kidney disease, cancer and use of all cardiovascular drugs were more common among glucocorticoid users than among non-users.
Recurrent ischemic stroke, hemorrhagic stroke, myocardial infarction, and venous thromboembolism A total of 589 patients (3.3% of all patients experiencing an outcome) had more than one outcome. After ischemic stroke, the 1-year cumulative risk of recurrent ischemic stroke was high among current glucocorticoid users (16.5%), whereas the risks of hemorrhagic stroke (0.46%), myocardial infarction (1.35%) and venous thromboembolism (1.05%) were markedly lower (Fig. 1) .
Among current users, the 1-year aHR for recurrent ischemic stroke was close to unity as compared with nonusers (aHR 1.01, 95% CI 0.93-1.10). Estimates were similar for former, new and long-term users ( Table 2 ). The risk of hemorrhagic stroke was lower among current glucocorticoid users (aHR 0.60, 95% CI 0.38-0.93), whereas the risks of myocardial infarction (aHR 1.32, 95% CI: 0.98-1.76) and venous thromboembolism (aHR 1.39, 95% CI 0.99-1.94) were increased. When we analyzed provoked and unprovoked venous thromboembolism separately, our results agreed with the main results. The results of separate analyses of specified ischemic stroke and unspecified stroke also agreed with the main results (Tables S3 and S4 ). Estimates for new and long-term use agreed with the finding for current use, albeit with less precision (Table 2) . Estimates were similar for former use and current use as compared with non-use for recurrent ischemic stroke, hemorrhagic stroke, and venous thromboembolism. No increased risk of myocardial infarction was found for former users versus non-users. When we compared current use directly with former use, the results remained similar to the results for current versus non-use for recurrent ischemic stroke and myocardial infarction, but approximated unity for hemorrhagic stroke and venous thromboembolism (Table S5 ).
In analyses examining the current use of increasing doses of glucocorticoid, the estimates agreed with those of the main analysis. No clear dose-response relationship was observed for any outcome (Table 3) .
Additional analyses
In sex-stratified and age-stratified analyses, there was no substantial modification of the association, although we observed slightly stronger associations among females for myocardial infarction and among males for venous thromboembolism. There was a tendency for there to be attenuation of the associations with increasing age. In analyses stratified by the presence/absence of cardiovascular disease, the aHR was consistently higher among patients without disease, presumably because of their lower baseline hazard. The same pattern was observed when stratification by diseases for which glucocorticoids are often prescribed (rheumatoid arthritis and related diseases, connective tissue disease, chronic pulmonary disease, and inflammatory bowel disease) was performed, although precision was compromised by small strata. Finally, results largely agreed between the early study period (2004) (2005) (2006) (2007) (2008) and the later study period (2009-2013) (Table S6) . 
Sensitivity analyses
The results remained robust in the analysis restricted to diagnoses of ischemic stroke confirmed by computed tomography or magnetic resonance imaging (Table S7) and in analyses using a 60-day or 30-day exposure window (Tables S8 and S9 ).
Discussion
Among patients with a first-time ischemic stroke, we found a 1.3-fold increased risk of myocardial infarction and a 1.4-fold increased risk of venous thromboembolism among current users of glucocorticoids as compared with non-users. We found no increased risk of recurrent CI, confidence interval. *Adjusted for sex, age group, and the individual comorbidities and comedications listed in Table 1 . ischemic stroke and a moderately decreased risk of hemorrhagic stroke among current users of glucocorticoids. No clear dose-response relationship was observed with increasing doses of glucocorticoids. Among former glucocorticoid users versus non-users, there were no substantial associations with recurrent ischemic stroke and myocardial infarction, suggesting that confounding by indication did not play an important role. However, former use increased the risk of venous thromboembolism to the same extent as current use. This could have been caused by confounding by indication, especially because inflammatory diseases, for which glucocorticoids are commonly prescribed, are strongly associated with venous thromboembolism. However, another explanation may be a prolonged effect of glucocorticoids on the risk of venous thromboembolism.
The risks of myocardial infarction and venous thromboembolism among users of glucocorticoids in the general population have been established previously [17, 18] . A cohort study by Varas-Lorenzo et al. reported an increased risk of myocardial infarction, comparable with our finding, within an ischemic stroke population (odds ratio of 1.42, 95% CI 1.17-1.72) [17] . Johannesdottir et al. conducted a nested case-control study in the framework of a nationwide population-based cohort, and reported an increased risk of venous thromboembolism that exceeded our findings for ischemic stroke patients (adjusted incidence rate ratio of 2.31, 95% CI 2.18-2.45) [18] .
The present study extends the findings of a recent study that reported an association between current glucocorticoid use and an increased risk of short-term all-cause mortality after ischemic stroke, in a dose-responsive manner [10] . The clinical pathways responsible for this increased mortality remain unclear. For each outcome, the present study demonstrated opposite directions for cumulative incidence and relative risks. Hence, the increased relative risks of myocardial infarction and venous thromboembolism and the slightly decreased relative risk of hemorrhagic stroke should be interpreted in the light of low cumulative incidence rates. In contrast, the relative risk of recurrent ischemic stroke was not increased despite a much higher cumulative incidence. Therefore, if the indication for use is well justified, glucocorticoids for patients with ischemic stroke seem to be tolerable in relation to the risk of the particular outcomes that we examined.
There may be several mechanisms driving the increased risk of myocardial infarction and venous thromboembolism in current users of glucocorticoids with ischemic stroke, and they are probably related to the pleiotropic effects of glucocorticoids. First, the increased risk of myocardial infarction and venous thromboembolism found only in current users is in line with a drug effect on thrombocytes and the coagulation system. Hence, experimental studies have revealed that glucocorticoids enhance both the synthesis and the secretion of von Willebrand factor and plasminogen activator inhibitor-1, indicating that glucocorticoids may directly activate coagulation and inhibit fibrinolysis [19] . Second, glucocorticoids may increase plasma volume through a mineralocorticoid-like action [6] , which, in turn, may additionally stress the cardiovascular system in the course of an ischemic stroke. Third, long-term glucocorticoid use is associated with increased risks of atherosclerosis, diabetes mellitus, and hypertension [6] , which are wellknown risk factors for myocardial infarction [20] . The prothrombotic and procoagulant effects of glucocorticoids may also be at the root of the decreased risk of hemorrhagic stroke. However, such effects cannot explain the null result for recurrent ischemic stroke. The reason may be the markedly increased absolute risk of recurrent ischemic stroke, when the use of glucocorticoids will probably have a minor impact on the relative scale. Also, glucocorticoids -or the underlying diseases for which glucocorticoids are prescribed -may contraindicate poststroke antithrombotic regimens, because of the risk of, for example, gastrointestinal bleeding. This could partly underlie the decreased risk of hemorrhagic stroke observed in our data.
Important strengths of our study include its population-based design within the setting of a free, tax-supported healthcare system with equal access, which largely eliminates referral and selection biases. The study population was large, providing precise overall estimates and the possibility for an array of subgroup and sensitivity analyses. The positive predictive values of ischemic stroke [15] , myocardial infarction and venous thromboembolism [21] have been reported to exceed 90%. Thus, misclassification should have had no significant influence on our results.Also, the data in the prescription database are complete [11] , and systemic glucocorticoids are not sold over the counter in Denmark. As glucocorticoids have a direct beneficial effect on a wide range of symptoms, and as copayment is required upon redemption, adherence was presumably high. Any misclassification of drug exposure because of non-adherence was probably independent of the outcomes, and would therefore attenuate the estimates of association towards unity. Because we classified unspecified strokes as ischemic strokes, a few hemorrhagic strokes were inevitably misclassified as ischemic strokes [15] . This misclassification was most likely small in extent and non-differential [15] , and would also bias the estimates for recurrent ischemic stroke and hemorrhagic stroke towards the null.
Despite confounder adjustment, our non-randomized study may be vulnerable to residual and unmeasured confounding. Specifically, residual confounding by non-steroidal anti-inflammatory drug use cannot be ruled out, as low-dose (≤ 200 mg) non-steroidal anti-inflammatory drugs are sold over the counter [22] . Furthermore, confounding by indication of the underlying diseases that lead to glucocorticoid use may have biased our results, and could partly explain the increased risks of myocardial infarction and venous thromboembolism.
In conclusion, preadmission use of glucocorticoids was associated with moderately increased risks of myocardial infarction and venous thromboembolism after first-time ischemic stroke, and a moderately decreased risk of hemorrhagic stroke, whereas no impact on recurrent ischemic stroke was observed. Table S1 . ICD and ATC codes. Table S2 . Definition of provoked venous thromboembolism. We defined patients with 'provoked' venous thromboembolism as those with a hospital discharge diagnosis of malignancy (any time before the venous thromboembolism diagnosis), or pregnancy/delivery, trauma/ fracture or surgery within 90 days preceding the date of the venous thromboembolism diagnosis. Table S3 . Preadmission glucocorticoid use and 1-year estimates following ischemic stroke, by provoked and unprovoked venous thromboembolism. Table S4 . Preadmission glucocorticoid use and 1-year estimates following ischemic stroke, by unspecified stroke and specified ischemic stroke. Table S5 . Sensitivity analysis: current versus former glucocorticoid use and 1-year estimates following ischemic stroke. Table S6 . Preadmission glucocorticoid use and 1-year risk of myocardial infarction, recurrent stroke, and venous thromboembolism, by sex, age group, comorbidity, and use of medications. Table S7 . Preadmission glucocorticoid use and 1-year estimates following ischemic stroke, with confirmation of ischemic stroke diagnosis with computed tomography scan or magnetic resonance imaging during admission. Table S8 . Preadmission glucocorticoid use and 1-year estimates following ischemic stroke, with a 60-day exposure window. Table S9 . Preadmission glucocorticoid use and 1-year estimates following ischemic stroke, with a 30-day exposure window.
